MedTrace Logo

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes

NCT06120556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2024-01-30

No results posted yet for this study

Summary

The goal of this observational retrospective study is to understand whether glucagon-like peptide-1 receptor agonists (GLP-1RA), which are a group of antidiabetes drugs, may act differently in different subtypes of patients with type 2 diabetes.

The main questions it aims to answer are:

* people with type 2 diabetes belonging to specific subtypes respond better (or worse) to GLP-1RA?
* the beneficial effect of GLP-1RA may last longer in people with type 2 diabetes belonging to specific subtypes?
* what are the clinical characteristics that better explain the efficacy and durability of GLP-1 receptor agonists in type 2 diabetes management?

Clinical data from records of patients attending the diabetes outpatient clinic of our facility will be retrieved to compare the outcomes of GLP-1 receptor agonists in patients belonging to four subtypes of type 2 diabetes.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GLP-1 receptor agonist

Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.

Sponsors & Collaborators

  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

    lead OTHER

Principal Investigators

  • Francesco Giorgino, PhD · University of Bari Aldo Moro

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-10
Primary Completion
2023-10-31
Completion
2023-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06120556 on ClinicalTrials.gov